Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: New audiological results from a prospective, open, uncontrolled, monocentric phase i study

Cancer Chemotherapy and Pharmacology

Volumn 77, Issue 2, 2016, Pages 413-427

  König, Miriam ^a   Von Hagens, Cornelia ^b   Hoth, Sebastian ^a   Baumann, Ingo ^a   Walter Sack, Ingeborg ^b   Edler, Lutz ^c   Sertel, Serkan ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Artesunate; Breast cancer; Metastasis; Ototoxicity

Indexed keywords

ARTESUNATE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

ACOUSTIC REFLEX; ADD ON THERAPY; ADULT; AGED; ARTICLE; AUDIOMETER; BREAST METASTASIS; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEARING IMPAIRMENT; HUMAN; LONG TERM CARE; MIDDLE AGED; OPEN STUDY; OTOTOXICITY; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PURE TONE AUDIOMETRY; SUBCLINICAL HEARING LOSS; TINNITUS; VERTIGO; AUDIOMETRY; BREAST NEOPLASMS; CANCER STAGING; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; DRUG MONITORING; METASTASIS; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; TUMOR INVASION;

ADULT; ANTIMALARIALS; ARTEMISININS; AUDIOMETRY; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; TREATMENT OUTCOME; VERTIGO;

EID: 84958055473     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-016-2960-7     Document Type: Article

References (34)

1. Davis TM, Karunajeewa HA, Ilett KF (2005) Artemisinin-based combination therapies for uncomplicated malaria. Med J Aust 182(4):181-185
2. World Health Organization (2006) Guidelines for the treatment of malaria. World Health Organization, Geneva
3. Sun WC, Han JX, Yang WY, Deng DA, Yue XF (1992) Antitumor activities of 4 derivatives of artemisic acid and artemisinin B in vitro. Zhongguo Yao Li Xue Bao 13(6):541-543
4. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR (2001) The anti-malarial artesunate is also active against cancer. Int J Oncol 18(4):767-773
5. Li Y, Shan F, Wu JM, Wu GS, Ding J, Xiao D, Yang WY, Atassi G, Leonce S, Caignard DH, Renard P (2001) Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle. Bioorg Med Chem Lett 11(1):5-8
6. Singh NP, Lai H (2001) Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci 70(1):49-56
7. Reungpatthanaphong P, Mankhetkorn S (2002) Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines. Biol Pharm Bull 25(12):1555-1561
8. Disbrow GL, Baege AC, Kierpiec KA, Yuan H, Centeno JA, Thibodeaux CA, Hartmann D, Schlegel R (2005) Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. Cancer Res 65(23):10854-10861. doi: 10.1158/0008-5472.CAN-05-1216
9. Chen HH, Zhou HJ, Wang WQ, Wu GD (2004) Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer Chemother Pharmacol 53(5):423-432. doi: 10.1007/s00280-003-0751-4
10. Dell'Eva R, Pfeffer U, Vene R, Anfosso L, Forlani A, Albini A, Efferth T (2004) Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem Pharmacol 68(12):2359-2366. doi: 10.1016/j.bcp.2004.08.021
11. Moore JC, Lai H, Li JR, Ren RL, McDougall JA, Singh NP, Chou CK (1995) Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. Cancer Lett 98(1):83-87
12. Berger TG, Dieckmann D, Efferth T, Schultz ES, Funk JO, Baur A, Schuler G (2005) Artesunate in the treatment of metastatic uveal melanoma-first experiences. Oncol Rep 14(6):1599-1603
13. Singh NP, Verma KB (2002) Case report of a laryngeal squamous cell carcinoma treated with artesunate. Arch Oncol 10(4):279-280
14. Genovese RF, Newman DB, Brewer TG (2000) Behavioral and neural toxicity of the artemisinin antimalarial, arteether, but not artesunate and artelinate, in rats. Pharmacol Biochem Behav 67(1):37-44
15. Genovese RF, Newman DB, Li Q, Peggins JO, Brewer TG (1998) Dose-dependent brainstem neuropathology following repeated arteether administration in rats. Brain Res Bull 45(2):199-202
16. Kissinger E, Hien TT, Hung NT, Nam ND, Tuyen NL, Dinh BV, Mann C, Phu NH, Loc PP, Simpson JA, White NJ, Farrar JJ (2000) Clinical and neurophysiological study of the effects of multiple doses of artemisinin on brain-stem function in Vietnamese patients. Am J Trop Med Hyg 63(1-2):48-55
17. Van Vugt M, Angus BJ, Price RN, Mann C, Simpson JA, Poletto C, Htoo SE, Looareesuwan S, White NJ, Nosten F (2000) A case-control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg 62(1):65-69
18. McCall MB, Beynon AJ, Mylanus EA, van der Ven AJ, Sauerwein RW (2006) No hearing loss associated with the use of artemether-lumefantrine to treat experimental human malaria. Trans R Soc Trop Med Hyg 100(12):1098-1104. doi: 10.1016/j.trstmh.2006.02.017
19. Toovey S, Jamieson A (2004) Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg 98(5):261-267; discussion 268-269. doi: 10.1016/j.trstmh.2003.11.001
20. Mehta U, Barnes KI, Kathard H, Vugt M, Durrheim D (2005) Comment on: audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg 99(4):313-314; author reply 314-315. doi: 10.1016/j.trstmh.2004.11.006
21. Hutagalung R, Htoo H, Nwee P, Arunkamomkiri J, Zwang J, Carrara VI, Ashley E, Singhasivanon P, White NJ, Nosten F (2006) A case-control auditory evaluation of patients treated with artemether-lumefantrine. Am J Trop Med Hyg 74(2):211-214
22. Reinhart H, Hughson C, de Palacios PI (2005) Comment on: audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg 99(4):315-316; author reply 316-317. doi: 10.1016/j.trstmh.2004.11.008
23. Panossian LA, Garga NI, Pelletier D (2005) Toxic brainstem encephalopathy after artemisinin treatment for breast cancer. Ann Neurol 58(5):812-813. doi: 10.1002/ana.20620
24. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Dehaes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European-Organization-for-Research-and-Treatment-of-Cancer Qlq-C30 - a quality-of-life instrument for use in international clinical-trials in oncology. J Natl Cancer I 85(5):365-376. doi: 10.1093/jnci/85.5.365
25. Sertel S, Eichhorn T, Sieber S, Sauer A, Weiss J, Plinkert PK, Efferth T (2010) Factors determining sensitivity or resistance of tumor cell lines towards artesunate. Chem Biol Interact 185(1):42-52. doi: 10.1016/j.cbi.2010.02.002
26. Sertel S, Eichhorn T, Simon CH, Plinkert PK, Johnson SW, Efferth T (2010) Pharmacogenomic identification of c-Myc/Max-regulated genes associated with cytotoxicity of artesunate towards human colon, ovarian and lung cancer cell lines. Molecules 15(4):2886-2910. doi: 10.3390/molecules15042886
27. Krishna S, Bustamante L, Haynes RK, Staines HM (2008) Artemisinins: their growing importance in medicine. Trends Pharmacol Sci 29(10):520-527. doi: 10.1016/j.tips.2008.07.004
28. Firestone GL, Sundar SN (2009) Anticancer activities of artemisinin and its bioactive derivatives. Expert Rev Mol Med 11:e32. doi: 10.1017/S1462399409001239
29. Krishna S, Ganapathi S, Ster IC, Saeed ME, Cowan M, Finlayson C, Kovacsevics H, Jansen H, Kremsner PG, Efferth T, Kumar D (2015) A randomised, double blind, placebo-controlled pilot study of oral artesunate therapy for colorectal cancer. EBioMedicine 2(1):82-90. doi: 10.1016/j.ebiom.2014.11.010
30. Carrasquilla G, Baron C, Monsell EM, Cousin M, Walter V, Lefevre G, Sander O, Fisher LM (2012) Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether-lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 86(1):75-83. doi: 10.4269/ajtmh.2012.11-0192
31. Carrara VI, Phyo AP, Nwee P, Soe M, Htoo H, Arunkamomkiri J, Singhasivanon P, Nosten F (2008) Auditory assessment of patients with acute uncomplicated Plasmodium falciparum malaria treated with three-day mefloquine-artesunate on the north-western border of Thailand. Malar J 7:233. doi: 10.1186/1475-2875-7-233
32. Gurkov R, Eshetu T, Miranda IB, Berens-Riha N, Mamo Y, Girma T, Krause E, Schmidt M, Hempel JM, Loscher T (2008) Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial. Malar J 7:179. doi: 10.1186/1475-2875-7-179
33. Schmutzhard J, Kositz CH, Lackner P, Dietmann A, Fischer M, Glueckert R, Reindl M, Stephan K, Riechelmann H, Schrott-Fischer A, Schmutzhard E (2010) Murine malaria is associated with significant hearing impairment. Malar J 9:159. doi: 10.1186/1475-2875-9-159
34. Adjei GO, Goka BQ, Kitcher E, Rodrigues OP, Badoe E, Kurtzhals JA (2013) Reversible audiometric threshold changes in children with uncomplicated malaria. J Trop Med 2013:360540. doi: 10.1155/2013/360540